ICH Q8, 9 & 10 and the Impact on the QP
|
|
- Elwin Gray
- 5 years ago
- Views:
Transcription
1 1 ICH Q8, 9 & 10 and the Impact on the QP Peter H. Gough David Begg Associates phg@david-begg-associates.com
2 2 A New Approach to Regulation Approach to the regulation of pharmaceuticals is undergoing a paradigm shift Led by the American Food and Drug Administration (FDA) Started with Process Analytical Technology (PAT) and 21st Century GMP initiatives. These changes will directly impact on many aspects of quality management and the QP.
3 FDA s Concerns Current State of Pharmaceutical Manufacturing: Many product formulations and processes derived empirically Too little knowledge on fundamental mechanisms impacting product quality Very low efficiency and high cost Industry hesitant or afraid to use new technologies
4 FDA s Concerns FDA s CONCLUSION: Current approach likely to be inadequate to meet future needs FDA unable to deliver on their statutory inspection obligations Need to encourage greater emphasis on science and risk-based approaches
5 5 FDA Initiatives since 2001 PAT cgmp ICH GMP activities Critical Path Desired State
6 6 Process Analytical Technology (PAT) Not just testing but a philosophy of Control in-process rather than endproduct testing Minimises risks of poor quality
7 7 PAT Approach Quality by Design Identify the parameters that are critical to product quality Statistically designed experiments Measure these parameters Control these parameters Feed back Feed forward
8 8 Paradigm Shift Current paradigm: Starting Materials Processing parameters Product Variable Fixed Variable
9 9 Paradigm Shift PAT paradigm: Starting Materials Processing parameters Product Variable Variable Fixed
10 10 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals (ICH) for Human Use
11 11 ICH Participants Expert Working Groups (EWGs) Q uality S afety E fficacy M ultidisciplinary
12 12 ICH GMP Guidance EU, Japan and observers joined USA to define a new paradigm at an ICH GMP Workshop in Brussels, July 2003 Three guidance documents: Q8, on Pharmaceutical Development Q9, on Quality Risk Management Q10, on Pharmaceutical Quality Systems
13 13 Flexible Regulatory Approach Regulators evaluate risk, based on: Product and process design (Q8) Measures to evaluate and manage risks (Q9) Quality system implementation (Q10) Regulators determine risk and modify level of oversight accordingly for: Submissions Post-approval change review GMP inspections Result: Removal of barriers to continuous improvement Efficient use of resources by industry and regulators
14 14 ICH Quality GMP Related Activities - Current Status Q8 Pharmaceutical Development Approved by ICH in November 2005 Implemented in EU, Japan and USA during 2006 Q8(R1) at Step 3 of ICH process Q9 Quality Risk Management Approved by ICH in November 2005 Implemented in Japan & USA during 2006 but not yet in EU Q10 Pharmaceutical Quality Systems Draft formally issued for comment Expect final ICH approval in Spring of 2008
15 15 ICH Q8 Pharmaceutical Development
16 16 Q8 seeks to Deliver Product quality and performance achieved and assured by design of effective manufacturing processes Product specifications based on mechanistic understanding of how formulation and process factors impact product performance An ability to affect continuous improvement and continuous "real time" assurance of quality
17 17 Q8 Key Concepts Q8 is the way that PAT concepts can be integrated with the Regulatory process Information from pharmaceutical development studies is a basis for risk management (using Q9) Identify critical parameters, which carry the risk This assessment helps define the design space
18 18 Design Space Design space is the multidimensional combination and interaction of input variables (e.g. material attributes) and process parameters that have been demonstrated to provide assurance of quality.
19 19 Design Space Knowledge Space Design Space Batch process settings The batch process settings are NOT registered and, hence, moving them within the Design Space is NOT a change
20 20 Design Space Design space is the multidimensional combination and interaction of input variables (e.g. material attributes) and process parameters that have been demonstrated to provide assurance of quality.
21 21 n-dimensional Design Space Peat Describing Flavour Coffee (Flavour Space) Sweet Toast Batch process settings Interaction 2 Design Space n-d (Bulk Blend) % Moisture Particle Size Tobacco Chocolate Interaction 1 Surface Area Cinnamon % lubricant
22 22 ICH Q8 (R1) Received Step 2 approval 1 Nov Hoped to reach Step 4 in June 2008 ICH Q8 (R1) provides an annex to Q8 guideline. This annex elaborates the elements of pharmaceutical development as: Target Product Profile Critical Quality Attributes (CQA) Linking material attributes and process parameters to CQAs by risk assessment Design Space Control Strategy Product lifecycle management and continual improvement
23 23 ICH Q8 (R1) Design Space Concept of Design Space is elaborated upon with guidance on: Selection of variables Defining and describing a design space in a submission Unit operation design space(s) Relationship of Design Space to scale and equipment Design Space versus proven acceptable ranges Design Space and edge of failure
24 24 ICH Q8 (R1) Appendix 1 - Overall Development Minimal Approach Mainly empirical Developmental research often conducted one variable at a time QbD Approach Systematic, relating mechanistic understanding of input material attributes and process parameters to drug product CQAs Multivariate experiments to understand product and process Establishment of design space PAT tools utilised
25 25 ICH Q9 Quality Risk Management
26 26 ICH Q9 - Principles of Quality Risk Management Two primary principles: 1. The evaluation of the risk to quality should be based on scientific knowledge and ultimately link to the protection of the patient. 2. The level of effort, formality and documentation of the quality risk management process should be commensurate with the level of risk.
27 27 ICH Q9 Quality Risk Management Process
28 28 Risk Management Methodology Failure Mode Effects Analysis (FMEA) Failure Mode Effects & Criticality Analysis (FMCEA) Fault Tree Analysis (FTA) Hazard Analysis of Critical Control Points (HACCP) Hazard Operability Analysis (HAZOP) Risk Ranking and Filtering Preliminary Hazard Analysis (PHA) Supporting statistical tools Annex I: Short description Potential areas of use
29 29 Q9 - Implementation in EU Q9 was fully implemented in USA and Japan in 2006 NOT yet implemented in EU EMEA Q9 Implementation Group consisting of inspectors and regulatory assessors EU adoption expected to be as follows: Added as Annex 20 of GMP Guide Changes to Introduction and Chapter 1 of EU GMP Guide Revisions to some CHMP NfGs
30 30 ICH Q10 Pharmaceutical Quality Systems
31 31 ICH Q10 Objective The objective is to describe a model for an effective quality management system for the pharma. industry, referred to as the pharmaceutical quality system, that: Ensures the realisation of a quality drug product Establishes and maintains a state of control Facilitates continual improvement over the product lifecycle
32 32 Q10 Introduction Q10 will: Augment existing GMPs Provide a bridge between different regional regulations Complement and facilitate implementation of Q8 Pharmaceutical Development and Q9 Quality Risk Management
33 33 Q10 Introduction Implementation of Q10 should facilitate: Innovation and continual improvement throughout the product lifecycle and Strengthen the link between pharmaceutical development and manufacturing organizations.
34 34 Q10 - Enablers The enablers provide the means for science- and risk-based decisions related to product quality Knowledge Management Manage knowledge from development through commercialisation to discontinuation Quality Risk Management (Q9) Proactive approach to managing risks to quality
35 35 The Desired State Product quality and performance achieved by design Specifications based on mechanistic understanding of how formulation and process factors impact product performance Continuous real time assurance of quality
36 36 Impact on the QP Data interpretation Many recent changes place significant focus on data evaluation : ICH Q8 ICH Q9 Product Quality Reviews On-going stability QPs must be have good understanding of statistical techniques for data interpretation
37 37 Data, Information, Knowledge & QP Decisions QP Decisions: Based on knowledge Knowledge: Derived from combining information sources Information: Data: Derived from data using statistical analysis Derived from relevant samples using validated methods QP Decision Knowledge Information Data
38 38 Impact on the QP Batch certification A QP s primary legal duty is to certify that product has been made in accordance with the Marketing Authorisation (MA) Current MAs have of a defined method of manufacture i.e. a fixed process Future MAs will define a Design Space
39 39 Impact on the QP Q8 & Design Space The Design Space may well be a mathematical algorithm that defines an n- dimensional space Real-time release Changes within the Design Space will not require regulatory submissions Who will Authorities hold accountable for ensuring that there is a system for managing changes within the Design Space? The Qualified Person!
40 40 Impact on the QP Quality Risk Management (Q9) A good understanding of Quality Risk Management (QRM) is going to be crucial Who will Authorities hold accountable for the QRM process and the final Risk Acceptance decision? The Qualified Person!
41 41 Impact on the QP Quality Systems (Q10) Senior management are ultimately responsible for the Quality System Who will they delegate the task of developing and implementing the PQS to? The Qualified Person?
42 42 Impact on the QP Quality Systems (Q10) The QP should NOT have to be the architect of the PQS The QP should be the auditor of the PQS The QP must monitor and be able to influence the content and implementation of the PQS
43 43 Impact on the QP Summary The new paradigm for pharmaceutical regulation is still developing QPs must keep up with the evolving expectations ICH Q8, 9 & 10 may be largely written but it is the interpretation over coming years that is going to be crucial for QPs QPs have the opportunity to influence the development of this new approach The QP is going to be key to implementing the new paradigm
44 44 Impact on the QP Summary The future for the QP is going to be much more interesting and stimulating than just reviewing batch records!
45
Challenges of Implementation of ICH Q 8
Challenges of Implementation of ICH Q 8 A Regulatory Perspective Dr. Susanne Keitel BioKorea, Seoul, September 2007 Overview of the Presentation ICH Q 8: Background; EU Experience Design Space Associated
More informationImplementing Quality Systems
Implementing Quality Systems CGMP By The Sea August 29, 2006 Chris Joneckis, Ph.D. Senior Advisor For CMC Issues Center For Biologics Evaluation And Research Add FDA Bar and Presentation Overview Driving
More informationQ8 and Q8 annex An industry Perspective
Workshop on Implementation of ICH Q8/Q9/Q10 and Other Quality Guidelines Beijing December 2008 Q8 and Q8 annex An industry Perspective Brian Withers, Abbott Laboratories, United Kingdom I attend this conference
More informationICH Q10 Pharmaceutical Quality System
Safeguarding public health ICH Q10 Pharmaceutical Quality System An EU Regulator s Perspective Presentation overview Why does Q10 exist and what were the desired outcomes Content of the Q10 step 2 document
More informationQuality by Design and OINDP. Today s Presentation
Quality by Design and OINDP Setting the Stage John C Berridge IPAC-RS September 2008 Today s Presentation QbD definition Setting the stage from an ICH perspective Future Opportunities 2 QbD Definition
More informationValue Paper. Are you PAT and QbD Ready? Get up to speed
Value Paper Are you PAT and QbD Ready? Get up to speed PAT and Quality-by-Design As PAT and Quality -by-design (QbD) become an integral part of the regulatory framework, automation group ABB argues more
More informationClaus Mortensen, Medicines Inspector. Danish Medicines Agency. Member of the EMEA PAT team
Claus Mortensen, Medicines Inspector Danish Medicines Agency Member of the EMEA PAT team EMEA progress and status what is needed to document scientific understanding in a PAT application EMEA PAT team
More informationQuality by Design. Innovate Design Development Create value. Correct definition of QbD and its relation to product and process development
Innovate Development Create value Quality by Correct definition of QbD and its relation to product and process development Dr John Loveluck 42 Technology Ltd +44 1480 302700 john.loveluck@42technology.com
More informationCMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D.
CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D. Senior Scientist (for Quality) Pharmaceuticals and Medical Devices Agency (PMDA) MFDS Nov 11, 2016 1 Agenda Introduction of PMDA ICH Q12 QbD assessment
More informationImportance of ICH Guidance in Fulfilling Process Validation Requirements
Importance of ICH Guidance in Fulfilling Process Validation Requirements Presented by: Gamal Amer All rights reserved. Do not copy without permission. Principal 1 Premier Compliance Services, Inc. Process
More informationInnovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series
CAMO European Pharmaceutical Seminars Jan/Feb 2009 Innovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series The Increasing Need of Multivariate Analysis for Process Understanding
More informationICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective
14 th DIA Japan Annual Meeting 2017 November 12-14, 2017 Tokyo Big Sight Ariake ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal Reviewer Office
More informationSTRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN
STRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN CHRISTOPHER J POTTER ISPE ADVISOR AND CMC CONSULTANT 1 AGENDA Background ICH Guidelines Terms and Definitions Supporting Information ISPE publications
More informationPHARMACEUTICAL QUALITY MANAGEMENT SYSTEM: A REVIEW
PHARMACEUTICAL QUALITY MANAGEMENT SYSTEM: A REVIEW Available online at www.ijdra.com REVIEW ARTICLE Sharma S*, Bodla R.B., Shweta S, Pathak D.P. Delhi Institute of Pharmaceutical Sciences and Research,
More informationQuality by Design, Clinical Relevance & Lifecycle Considerations
Quality by Design, Clinical Relevance & Lifecycle Considerations Robert Iser Acting Director Office of Process & Facilities / OPQ / CDER IFPAC 2016 1 FDA Quality Related Guidance and Initiatives Initiatives
More informationOSIsoft. Users Conference 2013
OSIsoft. Users Conference 2013 Pharmaceutical and Life Sciences: Towards a Recipe Driven Company and the Critical Role of the Real Time Infrastructure Continuous Process Verification By: Martin Browning,
More informationTechnology Transfer Plays an Increasingly Important Role in Pharmaceutical Quality Systems
Technology Transfer Plays an Increasingly Important Role in Pharmaceutical Quality Systems A robust and secure manufactured product is the desired end result for pharmaceutical companies. Scale-up and
More informationPROCESS ANALYTICAL TECHNOLOGY (PAT) - AS A CULTURE OF INNOVATION
International Journal of ChemTech Research CODEN( USA): IJCRGG ISSN : 0974-4290 Vol.1, No.4, pp 1339-1344, Oct-Dec 2009 PROCESS ANALYTICAL TECHNOLOGY (PAT) - AS A CULTURE OF INNOVATION Deepak D. Pokharkar*,
More informationQbD Application in Japan: PMDA Perspective
CMC Strategy Forum Japan 2013 Hotel Okura, Tokyo, Japan, December 9 10, 2013 QbD Application in Japan: PMDA Perspective Yasuhiro Kishioka, PhD. Reviewer Office of Cellular and Tissue based Products Pharmaceuticals
More informationFuture of Pharmaceutical Quality and the Path to Get There
Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research INTERPHEX 2018, April 18, 2018,
More informationCDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals
CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals Lawrence X. Yu, Ph.D. Director (acting) Office of Pharmaceutical Science Food and Drug Administration IFPAC
More informationEU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson
EU GMP Evolution or Revolution Scope and drivers for EU GMP changes August 2015 Gordon Farquharson EU & PIC/S Harmonisation at IWG level now Slide 2 PharmOut 2015 EU & PIC/S Harmonisation (1) What does
More informationProgressive Licensing and the Modernization of the Canadian Regulatory Framework
Progressive Licensing and the Modernization of the Canadian Regulatory Framework Workshop on Implementation of ICH Quality Guidelines Beijing, China 3-5 December, 2008 Mike Ward Health Canada 1 DISCLAIMER
More informationClaudio Pincus, President, The Quantic Group R. Owen Richards, President, Quantic Regulatory Services Daniel Pincus, Consultant, The Quantic Group
FDA Compliance and Regulatory Symposium Understanding the FDA s Latest cgmp Guidances: Opportunities and Pitfalls Claudio Pincus, President, The Group R. Owen Richards, President, Regulatory Services Daniel
More informationProgress in FDA s Drug Product Quality Initiative. Janet Woodcock, M.D. November 13, 2003
Progress in FDA s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003 Impetus for Initiative: Modernization and continuous improvement in pharmaceutical manufacturing sector slow compared
More informationMAH Responsibilities including the Management of CMOs. QP Forum Workshop. Robert Byrne and Eoin Duff Quality Assurance Alexion Pharmaceuticals
MAH Responsibilities including the Management of CMOs QP Forum 2017 - Workshop Robert Byrne and Eoin Duff Quality Assurance Alexion Pharmaceuticals 25 th April 2017 Alexion Pharmaceuticals in Ireland A
More informationInter-Association Task Force
Inter-Association Task Force Presentation to EMA Workshop Prevention of Drug Shortages Based on Quality and Manufacturing Issues 9 th October 2015 1 Topics for Today Background and history of task force
More informationICH Q-IWG Integrated Training Programme
Implementation of ICH Q8, Q9, Q10 ICH Q-IWG Integrated Training Programme International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Disclaimer
More informationAnalytical Methods and Sampling in the New Manufacturing Paradigm a Regulatory Perspective
Analytical Methods and Sampling in the New Manufacturing Paradigm a Regulatory Perspective Dr. Øyvind Holte Norwegian Medicines Agency EMA PAT team/ EDQM PAT working party 15 October, 2014, Heidelberg
More informationEuropean Commission Health and Consumers Directorate General, Brussels
PDA EUROPE Adalbertstr, 9 16548 Glienicke/Berlin Germany Tel: +49 33056 2377-0 or -10 Fax: +49 33056 2377-77 or -15 www.pda.org OFFICERS Chair Harold Baseman ValSource Chair-Elect Martin VanTrieste Amgen
More informationImpact of ICH Q9 and the application of Risk Management
Safeguarding public health Impact of ICH Q9 and the application of Risk Management An inspector s perspective on the impact on inspectional approaches and expectations Ian Thrussell Strategy and Development
More informationImplementation of ICH Q8 and QbD An FDA Perspective
ISPE, Yokohama, Japan June 9, 2006 Implementation of ICH Q8 and QbD An FDA Perspective Chi-wan Chen, Ph.D. Office of New Drug Quality Assessment Center for Drug Evaluation and Research Food and Drug Administration
More informationFeedback EMEA / Industry Discussion
Feedback EMEA / Industry Discussion Eli Lilly & Co Ltd Case Study: Use of In-Line Near-Infrared Spectroscopy to Monitor Segregation of a Pharmaceutical Powder Blend in a Tablet Press Martin Diller PhD,
More informationPMDA perspective on Quality by Design for pharmaceutical products
PMDA perspective on Quality by Design for pharmaceutical products Junichi Fukuchi, Ph.D. Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices Agency (PMDA) Annual conference
More informationEDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE : 20 YEARS OF EXPERIENCE March EDQM, Strasbourg, France ABSTRACTS
EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE 1992-2012: 20 YEARS OF EXPERIENCE 22-23 March 2012 EDQM, Strasbourg, France ABSTRACTS PLENARY SESSION, 22 March 2012 ABSTRACT 1.3 The Evolution
More informationQuality Risk Management
Quality Risk Management Iron Chef Edition Keith D. Gibbs kage and sui generis Ninja Project Management My story shapes my perspective Bachelor of Science work in Earth Science with focus on Hydrogeology.
More informationQUALITY: BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS
VICH GL 45 (QUALITY) BRACKETING AND MATRIXING April 2010 For Implementation at Step 7 QUALITY: BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS
More informationFrom API to Formulated Product
From API to Formulated Product Jean-Marie Geoffroy, PhD Director, Product Development Takeda Global Research & Development 675 N Field Drive Lake Forest, IL 60045 jean-marie.geoffroy@tgrd.com Acknowledgments
More informationAnalytical Development Labs
Analytical Development Labs S-Matrix ADL Purdue Technology Center 5225 Exploration Drive Suite S-2357 Indianapolis, IN 46241 USA URL: www.smatrix.com Overview Major Pharmaceutical companies worldwide use
More informationThe Process Analytical Technology Initiative: PAT and the Pharmacopeias
The Process Analytical Technology Initiative: PAT and the Pharmacopeias Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science CDER, FDA EDQM Spring Conference, Cannes, 3-43 4 May 2004
More informationWHO Regulatory Systems Strengthening Program
WHO Regulatory Systems Strengthening Program MVP RHT RSS CRS www.who.int Minimal capacity met Eligibility for vaccine PQ WHO listed NRAs WHO NRA 5 step capacity building Development of NRA benchmarking
More informationOffice of Pharmaceutical Quality Key Quality Initiatives
Office of Pharmaceutical Quality Key Quality Initiatives Ashley B. Boam, MSBE Director Office of Policy for Pharmaceutical Quality Office of Pharmaceutical Quality Center for Drug Evaluation and Research
More informationKeynote GMP & Validation from disaster, via overkill, to common sense.
Keynote GMP & Validation from disaster, via overkill, to common sense. Gordon Farquharson Melbourne - July 2016 1 My thoughts Power in the GMP world, leaders and followers. When validation became an industry.
More informationKEY HIGHLIGHTS WORKSHOP 2019
KEY HIGHLIGHTS aenvironmental Monitoring afacility Design apractical Case Studies avisual Inspection aclean Room Behaviours aprocess Simulations arecent 483s, warning Letters and EU Observations WORKSHOP
More informationICH Q7 - API. Presented by Ashley Isbel 4 July, 2016
ICH Q7 - API Presented by Ashley Isbel 4 July, 2016 ICH Q7 ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (November 2000) Adopted or referenced by: PIC/S in 2007 - Guide
More informationUpdate on Lessons Learned from the EMA-FDA QbD Pilot
Update on Lessons Learned from the EMA-FDA QbD Pilot IFPAC 2014 Annual Meeting 22 January 2014 Sharmista Chatterjee, Ph.D. CMC Lead for QbD, ONDQA/OPS/CDER/FDA Background One of the projected outcomes
More informationEDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality
EDQM Conference Quality of Medicines in a Globalised World: Dreams and Reality 14-15 October 2010 Prague, Czech Republic 2010 EDQM, Council of Europe, All rights reserved Plenary Session Dr Moheb M. Nasr
More informationICH Q8 / ICH Q11 Training Course
ICH Q8 / ICH Q11 Training Course From QbD to Process Validation Speakers: Dr Thomas Hille LTS Lohmann Therapie- Systeme AG Dr Øyvind Holte Norwegian Medicines Agency, EDQM PAT working party/ EMA PAT team
More informationGlobal Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation. Jane Weitzel
Global Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation Jane Weitzel mljweitzel@msn.com Jane Weitzel Biosketch Jane Weitzel has been working in analytical chemistry for over
More informationBuilding Toward a Modern Pharmaceutical Manufacturing Sector: Encouraging Development and Adoption of Emerging Technology
Building Toward a Modern Pharmaceutical Manufacturing Sector: Encouraging Development and Adoption of Emerging Technology Sau (Larry) Lee, Ph.D. Associate Director for Science Office of Pharmaceutical
More informationTowards malaria elimination: ADB-supported work at Myanmar FDA
Towards malaria elimination: ADB-supported work at Myanmar FDA Valerio Reggi 25 January 2018 Disclaimer: The views expressed in this paper/presentation are the views of the author and do not necessarily
More informationFSMA Update. Jennifer Thomas Interim Director for FSMA Operations Center for Food Safety and Applied Nutrition Food and Drug Administration May 2018
FSMA Update Jennifer Thomas Interim Director for FSMA Operations Center for Food Safety and Applied Nutrition Food and Drug Administration May 2018 Foundational Rules Regulation Final Rule Published Preventive
More informationTerrence Tougas. Dennis Sandell
Terrence Tougas Boehringer Ingeheim, Ridgefield, CT Dennis Sandell S5 Consulting, Lund, Sweden (c) 2011 Sandell & Tougas 1 Transforming the general concept of Quality into objective, well defined and actionable
More informationpeace of mind For from development to commercial supply
For peace of mind from development to commercial supply aesica-pharma.com weshouldtalk@aesica-pharma.com @aesica CorporateBroEng_v2 0814 @ Aesica 2014 Your full service CDMO Our vision: To be the number
More informationLeader in Pharmaceutical Films
TSX-V: IGX OTCQX: IGXT Leader in Pharmaceutical Films Your Specialist in Contract Development & Manufacturing WE MAKE APPROVED DRUGS BETTER Our Mission We make approved drugs better, with next generation
More informationWHITE PAPER FACILITY FOCUS: Next Generation Aseptic Manufacturing: An Eye-Opening Peek into the Future. By: Hite Baker
WHITE PAPER FACILITY FOCUS: Next Generation Aseptic Manufacturing: An Eye-Opening Peek into the Future By: Hite Baker August 2017 Introduction This Facility Focus Survey Report explores how to design sterile
More informationASEPTIC PROCESSING, TODAY AND FUTURE
ASEPTIC PROCESSING, TODAY AND FUTURE Dublin, Ireland, 4 October 2018 Marco Delgado Rueda ALL RIGHTS RESERVED 2018 PAREXEL INTERNATIONAL CORP. AGENDA Today s Reality and Needs Issues and Probable Causes
More information2008 Course Programs Schedule
2008 Course Programs Schedule Basic Laboratory Safety Laboratory Safety Biostatistics for the Non-Statistician - Basic Applied cgmps for Pharmaceutical and Allied Industries Good Clinical Practices (GCP)
More informationTechnology Transfer as the Process of Pharmaceutical Quality System: Modelling Technology Transfer as a Process Strategy
Journal of Pharmacy and Pharmacology 5 (2017) 299-313 doi: 10.17265/2328-2150/2017.06.002 D DAVID PUBLISHING Technology Transfer as the Process of Pharmaceutical Quality System: Modelling Technology Transfer
More informationFDA s Evolving Approach to Pharmaceutical Quality
FDA s Evolving Approach to Pharmaceutical Quality Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research 10th Annual FDA Inspections Summit Nov.
More informationQuality assurance in the supply chain for pharmaceuticals from the WHO perspective
1 Quality assurance in the supply chain for pharmaceuticals from the WHO perspective Dr Sabine Kopp Quality Assurance and Safety: Medicines Medicines Policy and Standards World Health Organization Presentation
More informationPDA 71 Years of Connecting People, Science and Regulation
PDA 71 Years of Connecting People, Science and Regulation 1 I m happy to be here. Bom Dia. Estou feliz por estar aqui. Richard M. Johnson PDA President & CEO since 2009 38 years experience in US and International
More informationCURRICULUM VITAE. Environment, Occupational Health and Safety)
CURRICULUM VITAE PERSONAL INFORMATION Name DIMITRIU LAVINIA CRISTINA Nationality Romanian Date of birth 13 August 1957 Sex Employer / Field of activity WORK EXPERIENCE female Antibiotice Quality Unit 25
More informationImplementation of Directive 2010/63/EU: - the animal welfare perspective
Animal experimentation Implementation of Directive 2010/63/EU: - the animal welfare perspective Kirsty Reid Scientific Officer Research Animals Eurogroup for Animals @KirstyEG4A 21 st May 2015 312 th session
More informationVENUE. 2 DAY WORKSHOP On FDA Penalties for Regulatory Non-Compliance in the Pharmaceuticals Industry in Review , JAN San Diego CA
WORLD COMPLIANCE SEMINARS SPEAKER:- BRIAN G. NADEL President of Brian G. Nadel, GMP Consulting, LLC. 2 DAY WORKSHOP On FDA Penalties for Regulatory Non-Compliance in the Pharmaceuticals Industry - 2017
More informationEDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality
EDQM Conference Quality of Medicines in a Globalised World: Dreams and Reality 14-15 October 2010 Prague, Czech Republic 2010 EDQM, Council of Europe, All rights reserved Dr Georges France Ms Suzette Kox
More informationQbD/PAT Implementation: The Road to RTR From Science to Compliance
Quality by Design China 2013 April 17-18, 2013 Shanghai, China Pedro Hernandez, PhD 何盼多博士 Senior Director Quality Assurance - China http://www.frontagelab.com pedrohernandez@frontagelab.com.cn Background
More informationConvergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA
EUnetHTA European network for Health Technology Assessment Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA University of Tokyo, October 24,
More informationHealth Based Exposure Limits (HBEL) and Q&As
Health Based Exposure Limits (HBEL) and Q&As The EMA guideline (EMA/CHMP/ CVMP/ SWP/169430/2012) & EMA/CHMP/CVMP/SWP/463311/2016 Graeme McKilligan, UK, MHRA. Content Intent of HBEL Post Implementation
More informationTechnology Needs Assessments under GEF Enabling Activities Top Ups
National Communications Support Programme United Nations Development Programme Global Environment Facility Technology Needs Assessments under GEF Enabling Activities Top Ups UNFCCC/UNDP Expert Meeting
More informationPolicy guidance regarding authorisation for Earth Stations on Vessels (ESVs)
Policy guidance regarding authorisation for Earth Stations on Vessels (ESVs) Publication date: September 2010 Earth Station on Vessels Contents Section Page 1 Policy Guidance regarding authorisation of
More informationPharmaceutical Manufacturing and Engineering Catalog Excerpt
Pharmaceutical Manufacturing and Engineering Catalog Excerpt PME 530 Introduction to Pharmaceutical Manufacturing Pharmaceutical manufacturing is vital to the success of the technical operations of a pharmaceutical
More informationUNITED NATIONS FRAMEWORK CONVENTION ON CLIMATE CHANGE DEVELOPMENT AND TRANSFER OF TECHNOLOGIES (DECISION 13/CP.1) Submissions by Parties
5 November 1998 ENGLISH ONLY UNITED NATIONS FRAMEWORK CONVENTION ON CLIMATE CHANGE CONFERENCE OF THE PARTIES * Fourth session Buenos Aires, 2-13 November 1998 Agenda item 4 (c) DEVELOPMENT AND TRANSFER
More informationARTES Competitiveness & Growth Full Proposal. Requirements for the Content of the Technical Proposal. Part 3B Product Development Plan
ARTES Competitiveness & Growth Full Proposal Requirements for the Content of the Technical Proposal Part 3B Statement of Applicability and Proposal Submission Requirements Applicable Domain(s) Space Segment
More informationRADIO SPECTRUM POLICY GROUP. Commission activities related to radio spectrum policy
EUROPEAN COMMISSION Directorate-General for Communications Networks, Content and Technology Electronic Communications Networks and Services Radio Spectrum Policy Group RSPG Secretariat Brussels, 03 October
More informationSection heading. Strapline sub-heading
Section heading Strapline sub-heading Smart every time NextPharma stands out as your pharmaceutical development and manufacturing partner with fast, flexible and tailored solutions for markets worldwide
More informationEmbracing Quality by Design. Applying QbD concepts can help CMOs create value
Embracing Quality by Design Applying QbD concepts can help CMOs create value By Russ Somma, Ph.D. and Andrew A. Signore, PE, PMP-DBIA, CPIP SommaTech, LLC Integrated Project Services (IPS) THE PHARMACEUTICAL
More informationApplied Safety Science and Engineering Techniques (ASSET TM )
Applied Safety Science and Engineering Techniques (ASSET TM ) The Evolution of Hazard Based Safety Engineering into the Framework of a Safety Management Process Applied Safety Science and Engineering Techniques
More informationGlobal GMP Harmonisation A Japanese Perspective
Global GMP Harmonisation A Japanese Perspective Yukio Hiyama, Ph.D. Chief, Third Section, Division of Drugs, National Institute of Health Sciences, The Ministry of Health Labour and Welfare, JAPAN ISPE
More informationOverview on Medicines Regulation: regulatory cooperation and harmonization in focus
Overview on Medicines Regulation: regulatory cooperation and harmonization in focus Dr Samvel Azatyan Manager, Medicines Regulatory Support Programme Quality Assurance and Safety: Medicines Essential Medicines
More informationHerts Valleys Clinical Commissioning Group. Review of NHS Herts Valleys CCG Constitution
Herts Valleys Clinical Commissioning Group Review of NHS Herts Valleys CCG s constitution Agenda Item: 14 REPORT TO: HVCCG Board DATE of MEETING: 30 January 2014 SUBJECT: Review of NHS Herts Valleys CCG
More informationChallenges, benefits, case study
hallenges, benefits, case study Pharmaceutical development phases overview The new paradigm for development: Quality by Design (QbD) hallenges Benefits ase study losure and Q&A»»»»»» D. eriani Meet MINITAB,
More informationThe Changing Face of Product and Process Development in the QbD Era. James Kraunsoe AstraZeneca Product Development UK/US
The Changing Face of Product and Process Development in the QbD Era James Kraunsoe AstraZeneca Product Development UK/US Disclaimer The views and opinions expressed in the following PowerPoint slides are
More informationATMP GMP requirements. Andrew Hopkins
Andrew Hopkins Scope GMP for ATMPs Points to consider Survey MHRA next steps Questions 2 GMP for ATMPs The usual process for GMP updates Problem statement submitted to IWG and PIC/S Reviewed and if accepted
More informationNZFSA Policy on Food Safety Equivalence:
NZFSA Policy on Food Safety Equivalence: A Background Paper June 2010 ISBN 978-0-478-33725-9 (Online) IMPORTANT DISCLAIMER Every effort has been made to ensure the information in this report is accurate.
More informationQuality Regulation under Revised Pharmaceutical Affair Law
Quality Regulation under Revised Pharmaceutical Affair Law Yukio Hiyama, Ph.D. Division of Drugs, National Institute of Health Sciences, the Ministry of Health, Labour and Welfare, Japan E mail hiyama@nihs.go.jp
More informationENCePP Work Plan
EMA/231507/2012 ENCePP Secretariat European Network of Centres for Pharmacoepidemiology and Pharmacovigilance European Network of Centres for Pharmacoepidemiology and Pharmacovigilance Adopted by the ENCePP
More informationHow CDER is Encouraging Adoption of Emerging Technologies in Pharmaceutical Industry
How CDER is Encouraging Adoption of Emerging Technologies in Pharmaceutical Industry Moderator: Lawrence Yu Speakers: Thomas O Connor & Sharmista Chatterjee Emerging Technology: A Key Enabler for Modernizing
More informationProcess Analytical Technology (PAT): A Real Time Quality Assurance
Review Article Process Analytical Technology (PAT): A Real Time Quality Assurance Punita Raj, N. Vishal Gupta* Pharmaceutical Quality Assurance group, JSS College of Pharmacy, JSS University, Sri Shivarathreeshwara
More informationPharmacovigilance Inspection Metrics Report
April 2013 - March 2014 Pharmacovigilance Inspection Metrics Report Introduction During the period 01 April 2013 to 31 March 2014, the Pharmacovigilance inspectorate conducted 56 inspections of Marketing
More informationTBT Provisions in RTAs: Do they go beyond the TBT Agreement?
TBT Provisions in RTAs: Do they go beyond the TBT Agreement? Xinyi Li Trade Policies Review Division, WTO Secretariat 12 th ARTNeT Capacity Building Workshop December 2016 1 Motives and Objectives TBT
More informationCurrent Status and Challenges of Bilateral/Multilateral Meetings
Current Status and Challenges of Bilateral/Multilateral Meetings Junko Sato, PhD International Liaison Officer PMDA 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views and
More informationHow Process Models can Facilitate Quality Risk Management for Emerging Technologies
How Process Models can Facilitate Quality Risk Management for Emerging Technologies Thomas O Connor, Ph.D. FDA-AIChE Workshop on Adopting Continuous Manufacturing North Bethesda, MD March 2 th, 2016 2
More informationOMCL Network of the Council of Europe GENERAL DOCUMENT
OMCL Network of the Council of Europe GENERAL DOCUMENT PA/PH/OMCL (09) 87 4R OMCL Network support for the implementation of the CoE MEDICRIME Convention Full document title and reference How the OMCL Network
More informationNCRIS Capability 5.7: Population Health and Clinical Data Linkage
NCRIS Capability 5.7: Population Health and Clinical Data Linkage National Collaborative Research Infrastructure Strategy Issues Paper July 2007 Issues Paper Version 1: Population Health and Clinical Data
More informationE5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E5 Implementation Working Group & (R1) Current version dated June 2, 2006 ICH Secretariat,
More informationCodex Committee on Fish and Fishery Products (31 st Session) Tromsø, Norway. (11-16 April 2011)
Codex Committee on Fish and Fishery Products (31 st Session) Tromsø, rway (11-16 April 2011) 14 October 2010 European Union comments on Circular Letter 2009/29-FFP - Part B.8 The European Union and its
More informationRFP/2017/015. Section 3
RFP/2017/015 Section 3 Terms of Reference (TOR) and Evaluation Criteria Study: Quality Infrastructure for Mini Grids of the Future Secretariat of the International Renewable Energy Agency (IRENA) I) BACKGROUND
More informationCOMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT. pursuant to Article 294(6) of the Treaty on the Functioning of the European Union
EUROPEAN COMMISSION Brussels, 9.3.2017 COM(2017) 129 final 2012/0266 (COD) COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT pursuant to Article 294(6) of the Treaty on the Functioning of the
More informationSymposium on Continuous Manufacturing of Pharmaceuticals Notes
1 2012 11 13 Symposium on Continuous Manufacturing of Pharmaceuticals Notes These are notes from the first open meeting regarding Novartis- MIT Center for Continuous Manufacturing (CCM). The meeting is
More information